نتایج جستجو برای: cml

تعداد نتایج: 6124  

Journal: :Blood 2010
Nicholas B Heaney Francesca Pellicano Bin Zhang Lisa Crawford Su Chu Syed M A Kazmi Elaine K Allan Heather G Jorgensen Alexandra E Irvine Ravi Bhatia Tessa L Holyoake

Chronic myeloid leukemia (CML) is treated effectively with tyrosine kinase inhibitors (TKIs); however, 2 key problems remain-the insensitivity of CML stem and progenitor cells to TKIs and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and proteasome inhibitors (PIs) are cytotoxic against CML cell lines. We demonstrate that bor...

Journal: :Environmental research 2012
Biki B Takashima-Uebelhoer Lisa G Barber Sofija E Zagarins Elizabeth Procter-Gray Audra L Gollenberg Antony S Moore Elizabeth R Bertone-Johnson

BACKGROUND Epidemiologic studies of companion animals offer an important opportunity to identify risk factors for cancers in animals and humans. Canine malignant lymphoma (CML) has been established as a model for non-Hodgkin's lymphoma (NHL). Previous studies have suggested that exposure to environmental chemicals may relate to development of CML. METHODS We assessed the relation of exposure ...

Journal: :Blood 2017
Anuradha Tarafdar Lisa E M Hopcroft Paolo Gallipoli Francesca Pellicano Jennifer Cassels Alan Hair Koorosh Korfi Heather G Jørgensen David Vetrie Tessa L Holyoake Alison M Michie

Targeting the fusion oncoprotein BCR-ABL with tyrosine kinase inhibitors has significantly affected chronic myeloid leukemia (CML) treatment, transforming the life expectancy of patients; however the risk for relapse remains, due to persistence of leukemic stem cells (LSCs). Therefore it is imperative to explore the mechanisms that result in LSC survival and develop new therapeutic approaches. ...

2016
David A. Irvine Bin Zhang Ross Kinstrie Anuradha Tarafdar Heather Morrison Victoria L. Campbell Hothri A. Moka Yinwei Ho Colin Nixon Paul W. Manley Helen Wheadon John R. Goodlad Tessa L. Holyoake Ravi Bhatia Mhairi Copland

Targeting the Hedgehog (Hh) pathway represents a potential leukaemia stem cell (LSC)-directed therapy which may compliment tyrosine kinase inhibitors (TKIs) to eradicate LSC in chronic phase (CP) chronic myeloid leukaemia (CML). We set out to elucidate the role of Hh signaling in CP-CML and determine if inhibition of Hh signaling, through inhibition of smoothened (SMO), was an effective strateg...

Journal: :PLoS ONE 2008
Young Kwang Chae Sung Koo Kang Myoung Sook Kim Janghee Woo Juna Lee Steven Chang Dong-Wook Kim Myungshin Kim Seonyang Park Inho Kim Bhumsuk Keam Jiyoung Rhee Nam Hee Koo Gyeongsin Park Soo-Hyun Kim Se-Eun Jang Il-Young Kweon David Sidransky Chulso Moon

Aquaporins (AQPs) have previously been associated with increased expression in solid tumors. However, its expression in hematologic malignancies including CML has not been described yet. Here, we report the expression of AQP5 in CML cells by RT-PCR and immunohistochemistry. While normal bone marrow biopsy samples (n = 5) showed no expression of AQP5, 32% of CML patient samples (n = 41) demonstr...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1999
F H Engels G K Koski I Bedrosian S Xu S Luger P C Nowell P A Cohen B J Czerniecki

Effective host T lymphocyte sensitization to malignant cells depends on successful antigen presentation. In this study, we examined the capacity of malignant myeloid progenitor cells of patients in the chronic phase of chronic myelogenous leukemia (CML) to acquire characteristics of activated dendritic cells (DCs) after intracellular calcium mobilization, thereby bypassing a need for third-part...

2018
Jixian Huang Ziyuan Lu Yajuan Xiao Bolin He Chengyun Pan Xuan Zhou Na Xu Xiaoli Liu

BACKGROUND A hypoxic microenvironment is associated with resistance to tyrosine kinase inhibitors (TKIs) and a poor prognosis in chronic myeloid leukemia (CML). The E3 ubiquitin ligase Siah2 plays a vital role in the regulation of hypoxia response, as well as in leukemogenesis. However, the role of Siah2 in CML resistance is unclear, and it is unknown whether vitaminK3 (a Siah2 inhibitor) can i...

Journal: :The Journal of clinical investigation 2011
Alexander Perl Martin Carroll

Chronic myeloid leukemia (CML) is a hematopoietic disease characterized by expansion of myeloid blood cells. It is caused by the t(9;22) chromosomal translocation that results in the expression of the fusion tyrosine kinase BCR-ABL. Tyrosine kinase inhibitor (TKI) therapy has led to long-term remissions, but patients remain BCR-ABL+. There is agreement that TKIs do not kill CML stem cells; howe...

2012
Rizwan Ahmad Ranjana Singh Anil Kumar Tripathi Raj Kumar Singh

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder of the hematopoietic cell and is associated with a characteristic chromosomal translocation called the Philadelphia chromosome. Clinically, CML is often divided into three phases; CML typically begins in the chronic phase (CML-CP) and in the absence of intervention and over the course of several years progresses to an accelerated ...

Journal: :The journals of gerontology. Series A, Biological sciences and medical sciences 2014
Heather E Whitson Alice M Arnold Laura M Yee Kenneth J Mukamal Jorge R Kizer Luc Djousse Joachim H Ix David Siscovick Russell P Tracy Stephen M Thielke Calvin Hirsch Anne B Newman Susan Zieman

BACKGROUND Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large co...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید